Patents by Inventor Stephen Shuttleworth
Stephen Shuttleworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9943519Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: June 26, 2014Date of Patent: April 17, 2018Assignees: Genentech, Inc., F. Hoffmann-La Roche AGInventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzer-Toste, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
-
Publication number: 20160152632Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: June 26, 2014Publication date: June 2, 2016Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzer-Toste, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
-
Patent number: 8987260Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.Type: GrantFiled: February 6, 2014Date of Patent: March 24, 2015Assignee: F. Hoffmann-La Roche AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Publication number: 20140309216Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: June 26, 2014Publication date: October 16, 2014Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzer-Toste, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
-
Patent number: 8802670Abstract: Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: April 24, 2007Date of Patent: August 12, 2014Assignees: F. Hoffmann-La Roche AG, Genentech, Inc.Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
-
Publication number: 20140221367Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Applicant: F. HOFFMANN-LA ROCHE AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Patent number: 8685968Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.Type: GrantFiled: November 5, 2012Date of Patent: April 1, 2014Assignee: F. Hoffmann-La Roche AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Publication number: 20130230585Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.Type: ApplicationFiled: November 5, 2012Publication date: September 5, 2013Applicant: F. HOFFMANN-LA ROCHE AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Patent number: 8450315Abstract: Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: October 29, 2010Date of Patent: May 28, 2013Assignees: Genentech, Inc., F. Hoffmann-La Roche AGInventors: Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson, Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss
-
Patent number: 8324206Abstract: A thienopyrimidine of formula (I): and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K with selectivity for the P110? subtype, and may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly those associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: GrantFiled: July 20, 2010Date of Patent: December 4, 2012Assignee: F. Hoffmann-La Roche AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Publication number: 20110105464Abstract: Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: October 29, 2010Publication date: May 5, 2011Inventors: Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson, Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss
-
Publication number: 20110065701Abstract: A thienopyrimidine of formula (I): and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K with selectivity for the P110? subtype, and may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly those associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: ApplicationFiled: July 20, 2010Publication date: March 17, 2011Inventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Patent number: 7846929Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: April 24, 2007Date of Patent: December 7, 2010Assignees: Genentech, Inc., Piramed LimitedInventors: Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson
-
Patent number: 7781433Abstract: A thienopyrimidine of formula (I): and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K with selectivity for the P110? subtype, and may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly those associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: GrantFiled: April 24, 2007Date of Patent: August 24, 2010Assignee: Piramed LimitedInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Publication number: 20080076758Abstract: Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: April 24, 2007Publication date: March 27, 2008Applicants: Piramed Limited, Genentech, Inc.Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel Sutherlin, Bing-Yan Zhu
-
Publication number: 20080076768Abstract: A thienopyrimidine of formula (I): and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K with selectivity for the P110? subtype, and may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly those associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: ApplicationFiled: April 24, 2007Publication date: March 27, 2008Applicant: PIRAMED LIMITEDInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Publication number: 20080039459Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: April 24, 2007Publication date: February 14, 2008Applicants: Plramed Limited, Genentech, Inc.Inventors: Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson
-
Publication number: 20070142384Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L1-P-L2-M-X-L3-A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.Type: ApplicationFiled: February 24, 2005Publication date: June 21, 2007Applicant: AMGEN INC.Inventors: Michelle Akerman, Jonathan Houze, Daniel Lin, Jinqian Liu, Jiwen Liu, Jian Luo, Zhihua Ma, Julio Medina, Wei Qiu, Jeffrey Reagan, Rajiv Sharma, Michael Schmitt, Stephen Shuttleworth, Ying Sun, Yingcai Wang, Jian Zhang, Liusheng Zhu
-
Publication number: 20060199796Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.Type: ApplicationFiled: August 12, 2005Publication date: September 7, 2006Applicant: Amgen Inc.Inventors: Xi Chen, Xiaoqi Chen, Richard Connors, Kang Dai, Ying Fu, Juan Jaen, Yong-Jae Kim, Leping Li, Mike Lizarzaburu, Jeffrey Mihalic, Stephen Shuttleworth
-
Publication number: 20060040965Abstract: Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.Type: ApplicationFiled: June 29, 2005Publication date: February 23, 2006Inventors: Christopher Farthing, Paul Faulder, Alexander Frenkel, Martin Harrison, Xianyun Jiao, Frank Kayser, David Kopecky, Jinqian Liu, Sarah Lively, Rajiv Sharma, Stephen Shuttleworth
